Drug intelligence / Profile preview

Xcell Amnio Matrix

Development stage: Unknown
Lead developer: New Horizon Medical Solutions
Modality: Cell Therapies
Administration: Topical

Overview

Xcell Amnio Matrix (XAM) is a next-generation lyophilized human amniotic membrane allograft developed by New Horizon Medical Solutions for the management of acute and chronic wounds, including diabetic foot ulcers (DFUs). The product is aseptically processed to preserve the native extracellular matrix (ECM) and a rich array of endogenous growth factors, which together provide a protective biological barrier and a structural scaffold to support cellular migration and tissue regeneration. XAM is designed for handling simplicity and is currently being evaluated in randomized controlled clinical trials as an adjunct to standard of care therapy to improve complete wound closure rates in patients with chronic ulcers.

Brand names: Xcell Amnio Matrix
Other names: Xcell

Beyond the preview

Go deeper on Xcell Amnio Matrix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xcell Amnio Matrix.

Explore the full profile